* SangStat Medical Corp., of Menlo Park, Calif., said pivotal trials ofits cyclosporine formulation demonstrated bioequivalence to themarketed version of the immunosuppressive drug, which is sold bySandoz Ltd., of Basel, Switzerland. Based on the study resultsSangStat expects to file for marketing clearance of its product by theend of this year under the FDA's guidelines for generic drugs.

(c) 1997 American Health Consultants. All rights reserved.

No Comments